Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.
Higher time in optimal glycemic range was associated with reduced risk for preeclampsia and for birth weight larger than gestational age, new research found.
The statistically significant improvements in MASH with survodutide were seen without worsening fibrosis and included a relative reduction of steatosis of 30%.